证券代码：688366 证券简称：昊海生科 公告编号：2025-038 上海昊海生物科技股份有限公司 三、《终止合作协议》的主要内容 视觉、乙方及丙方应促使并确保亨泰光学与甲方共同签署《终止确认函》，确认 《独家经销合同》及《技术授权合约书》于亨泰光学与卡尔蔡司《股份转换契约》 项下股份转换基准日前一日终止。 自愿披露关于签订《终止合作协议》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、前次交易的基本情况 司昊海生物科技控股有限公司（"昊海控股"）与亨泰光学股份有限公司（"亨 泰光学"）、上海亨泰视觉科技有限公司（"亨泰视觉"）签署《独家经销合同》 《技术授权合约书》（以下合称"独家经销协议"），约定亨泰光学授予亨泰视 觉高端角膜塑形用硬性透气接触镜产品（OK 镜）"迈儿康 myOK"于中国大陆 地区、期限为 10 年（截至 2030 年 12 月 31 日）的独家经销权，昊海控股作为采 购平台；并持续授予亨泰视觉儿童近视管理及控制的光学镜片"贝视得"于中国 大陆地区的独家经销权。同时，公司全资子公司上海昊海 ...

独家经销协议正式终止前，各方仍应当正常履行相关协议;在相关交接工作完成后，各方促使并确保亨 泰视觉少数股东金亨泰(厦门)贸易有限公司("金亨泰(厦门)")与昊海发展签署《股权转让协议》，以亨泰 视觉截至2025年9月30日止账面净资产为依据计算股权转让价格，金亨泰(厦门)将其所持有的亨泰视觉 45%股权全部转让给昊海发展，亨泰视觉将成为昊海发展全资子公司，继续纳入公司合并报表范围。 昊海生科(688366.SH)公告，因卡尔蔡司拟通过股份转换的形式收购亨泰光学100%股份，亨泰光学的控 制权将发生变更。公司子公司昊海控股与亨泰光学现有主要股东及利害关系人签署《终止合作协议》。 各方同意在《终止合作协议》签署后，促使并确保亨泰光学与昊海控股、亨泰视觉共同签署《终止确认 函》，并自亨泰光学与卡尔蔡司《股份转换契约》项下股份转换基准日前一日终止独家经销协议，亨泰 光学主要股东及利害关系人向昊海控股支付终止合作补助金8000万元。 ...

Core Viewpoint - Haohai Biology (688366.SH) announced that Carl Zeiss intends to acquire 100% of Hengtai Optical through a share conversion, resulting in a change of control over Hengtai Optical [1] Group 1: Agreement and Termination - Haohai Holdings and Hengtai Optical's existing major shareholders and stakeholders signed a "Termination Cooperation Agreement" [1] - All parties agreed to ensure that Hengtai Optical, Haohai Holdings, and Hengtai Vision sign a "Termination Confirmation Letter" after the "Termination Cooperation Agreement" is signed [1] - The exclusive distribution agreement will be terminated one day before the share conversion benchmark date between Hengtai Optical and Carl Zeiss, with Hengtai Optical's major shareholders and stakeholders paying a termination compensation of 80 million yuan to Haohai Holdings [1] Group 2: Share Transfer and Future Structure - Before the formal termination of the exclusive distribution agreement, all parties must continue to perform related agreements normally [1] - After the completion of relevant handover work, Hengtai Vision's minority shareholder, Jinhengtai (Xiamen) Trading Co., Ltd., will sign a "Share Transfer Agreement" with Haohai Development [1] - The share transfer price will be calculated based on Hengtai Vision's book net assets as of September 30, 2025, with Jinhengtai (Xiamen) transferring its entire 45% stake in Hengtai Vision to Haohai Development, making Hengtai Vision a wholly-owned subsidiary of Haohai Development and continuing to be included in the company's consolidated financial statements [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 海外監管公告 本公告乃由上海昊海生物科技股份有限公司（「本公司」）根據《香港聯合交易所有 限公司證券上市規則》第13.10B條的規定刊發。 茲載列本公司在上海證券交易所網站刊登之《上海昊海生物科技股份有限公司自 願披露關於簽訂<終止合作協議>的公告》，僅供參考。 承董事會命 上海昊海生物科技股份有限公司 主席 侯永泰 中國上海，2025年8月20日 於本公告日期，本公司之執行董事為侯永泰博士、吳劍英先生、陳奕奕女士及 唐敏捷先生；本公司之非執行董事為游捷女士、黃明先生及魏長征先生； 及本公司之獨立非執行董事為沈紅波先生、姜志宏先生、蘇治先生及楊玉社先生。 * 僅供識別 证券代码：688366 证券简称：昊海生科 ...

独家经销协议正式终止前，各方仍应当正常履行相关协议；在相关交接工作完成后，各方促使并确保亨 泰视觉少数股东金亨泰（厦门）贸易有限公司（"金亨泰（厦门）"）与昊海发展签署《股权转让协 议》，以亨泰视觉截至2025年9月30日止账面净资产为依据计算股权转让价格，金亨泰（厦门）将其所 持有的亨泰视觉45%股权全部转让给昊海发展，亨泰视觉将成为昊海发展全资子公司，继续纳入公司合 并报表范围。 格隆汇8月20日丨昊海生科(688366.SH)公布，因Carl Zeiss Vision International GmbH（"卡尔蔡司"）拟通 过股份转换的形式收购亨泰光学100%股份，亨泰光学的控制权将发生变更，进而对原合作带来重大变 化。经友好协商，昊海控股与亨泰光学现有主要股东及利害关系人签署《终止合作协议》。各方同意在 《终止合作协议》签署后，促使并确保亨泰光学与昊海控股、亨泰视觉共同签署《终止确认函》，并自 亨泰光学与卡尔蔡司《股份转换契约》项下股份转换基准日前一日终止独家经销协议，亨泰光学主要股 东及利害关系人向昊海控股支付终止合作补助金人民币8,000万元。 ...

证券代码：688366 证券简称：昊海生科 公告编号：2025-038 上海昊海生物科技股份有限公司 自愿披露关于签订《终止合作协议》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、前次交易的基本情况 2021 年 3 月 19 日，上海昊海生物科技股份有限公司（"公司"）全资子公 司昊海生物科技控股有限公司（"昊海控股"）与亨泰光学股份有限公司（"亨 泰光学"）、上海亨泰视觉科技有限公司（"亨泰视觉"）签署《独家经销合同》 《技术授权合约书》（以下合称"独家经销协议"），约定亨泰光学授予亨泰视 觉高端角膜塑形用硬性透气接触镜产品（OK 镜）"迈儿康 myOK"于中国大陆 地区、期限为 10 年（截至 2030 年 12 月 31 日）的独家经销权，昊海控股作为采 购平台；并持续授予亨泰视觉儿童近视管理及控制的光学镜片"贝视得"于中国 大陆地区的独家经销权。同时，公司全资子公司上海昊海医药科技发展有限公司 （以下简称"昊海发展"）与亨泰视觉及其股东签订《投资协议》，通过股权转 让以及增资的方式以人民币 2,50 ...

昊海生科公告，因Carl Zeiss Vision International GmbH拟通过股份转换形式收购亨泰光学100%股份，亨 泰光学控制权变更，导致原合作协议重大变化。经友好协商，昊海控股与亨泰光学主要股东签署《终止 合作协议》，亨泰视觉少数股东金亨泰（厦门）贸易有限公司将其持有的亨泰视觉45%股权转让给昊海 发展。此外，亨泰光学主要股东及利害关系人向昊海控股支付终止合作补助金人民币8000万元。该事项 无需提交董事会、股东会审议，公司与协议相对方不存在关联关系。 ...

Core Viewpoint - The company, Haohai Biological Technology Co., Ltd., has a current stock price of 56.75 yuan, with a rolling PE ratio of 31.94, marking a new low in 94 days, and a total market capitalization of 13.199 billion yuan [1] Company Summary - Haohai Biological specializes in the research, production, and sales of medical devices and pharmaceuticals, with key products including ophthalmic viscoelastic devices, artificial lenses, optical materials, hyaluronic acid, and medical chitosan [1] - The latest quarterly report for Q1 2025 shows the company achieved a revenue of 619 million yuan, a year-on-year decrease of 4.25%, and a net profit of 90.312 million yuan, down 7.41%, with a gross profit margin of 69.52% [1] Industry Summary - The average PE ratio for the medical device industry is 59.49, with a median of 40.19, positioning Haohai Biological at 61st place within the industry [2] - The company’s PE ratio is significantly lower than the industry average, indicating potential undervaluation compared to peers [2]

Group 1 - The latest stock price of Haohai Biological Technology is 55.18 yuan, an increase of 1.01% compared to the previous trading day [1] - The trading volume on the same day was 11,236 lots, with a total transaction amount of 0.62 billion yuan [1] - Haohai Biological Technology operates in the medical device industry, with its main business in pharmaceutical manufacturing, accounting for 99.83% of its operations [1] Group 2 - As of August 14, the company has completed its current share repurchase plan, having repurchased approximately 1.83 million A-shares, which represents 0.79% of the total share capital [1] - The average repurchase price was 56.7 yuan per share, with a total expenditure of approximately 1.04 billion yuan [1] - On August 15, the net outflow of main funds was 4.30 million yuan, with a cumulative net outflow of 4.95 million yuan over the past five days [1]

Core Viewpoint - The company has successfully completed its second phase of A-share repurchase, acquiring a total of 1,832,421 shares, which represents 0.79% of its total share capital, with a total expenditure of approximately 103.91 million yuan [1][3][4]. Summary by Sections Repurchase Plan and Approval - The repurchase plan was first disclosed on August 17, 2024, with a total expected repurchase amount between 100 million yuan and 200 million yuan, and a maximum repurchase price of 89.71 yuan per share [1]. - The board approved the repurchase on August 16, 2024, and the implementation period is from August 16, 2024, to August 15, 2025 [1]. Adjustments to Repurchase Price - Following the implementation of the 2024 semi-annual equity distribution, the maximum repurchase price was adjusted from 89.71 yuan to 89.31 yuan per share [2]. - After the 2024 annual equity distribution, the maximum repurchase price was further adjusted to 88.72 yuan per share [2]. Implementation Status - The company initiated the repurchase on November 26, 2024, and completed the repurchase by August 14, 2025, acquiring a total of 1,832,421 shares at an average price of 56.70 yuan per share [3][4]. - The total funds used for the repurchase amounted to approximately 103.91 million yuan, excluding taxes and transaction fees [3]. Share Distribution Changes - Prior to the repurchase, the total share count was 235,489,895 shares, which decreased to 232,581,095 shares post-repurchase [4][5]. - The repurchased shares will be used for employee stock ownership plans or equity incentives and will not enjoy voting rights or profit distribution during the holding period [6]. Future Plans for Repurchased Shares - The repurchased shares are intended to be transferred within three years; if not transferred, they will be canceled and the registered capital will be reduced accordingly [6].